Nuo Therapeutics, Inc. AURX revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Nuo Therapeutics, Inc. reported revenue across 2 products and services; the largest, Aurix And Private Label Kits, was $2.78M, 89.9% of the filed sum.
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Aurix And Private Label Kits$2.78M89.9%no prior
- Aurix And Private Label Centrifuge Devices$312K10.1%no prior
Members sum to $3.09M against $3.31M consolidated (residual $225K) - eliminations or corporate lines the filer did not tag on this axis.
- Product$1.22M94.0%+152.7% yoy
- License$77.9K6.0%no prior
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.